Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses by Harshbarger, Wayne D. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Schiffer Lab Publications Biochemistry and Molecular Pharmacology 
2021-01-25 
Unique structural solution from a VH3-30 antibody targeting the 
hemagglutinin stem of influenza A viruses 
Wayne D. Harshbarger 
Dana-Farber Cancer Institute 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/schiffer 
 Part of the Amino Acids, Peptides, and Proteins Commons, Influenza Virus Vaccines Commons, 
Medicinal Chemistry and Pharmaceutics Commons, Medicinal-Pharmaceutical Chemistry Commons, 
Pharmaceutics and Drug Design Commons, Structural Biology Commons, Virology Commons, and the 
Viruses Commons 
Repository Citation 
Harshbarger WD, Deming D, Lockbaum GJ, Attatippaholkun N, Kamkaew M, Hou S, Somasundaran M, 
Wang JP, Finberg RW, Zhu Q, Schiffer CA, Marasco W. (2021). Unique structural solution from a VH3-30 
antibody targeting the hemagglutinin stem of influenza A viruses. Schiffer Lab Publications. 
https://doi.org/10.1038/s41467-020-20879-6. Retrieved from https://escholarship.umassmed.edu/
schiffer/47 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Schiffer Lab 
Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
ARTICLE
Unique structural solution from a VH3-30 antibody
targeting the hemagglutinin stem of influenza A
viruses
Wayne D. Harshbarger1,5, Derrick Deming1,5, Gordon J. Lockbaum2, Nattapol Attatippaholkun 1,
Maliwan Kamkaew1, Shurong Hou 2, Mohan Somasundaran2, Jennifer P. Wang 3, Robert W. Finberg3,
Quan Karen Zhu 1, Celia A. Schiffer 2✉ & Wayne A. Marasco 1,4✉
Broadly neutralizing antibodies (bnAbs) targeting conserved influenza A virus (IAV)
hemagglutinin (HA) epitopes can provide valuable information for accelerating universal
vaccine designs. Here, we report structural details for heterosubtypic recognition of HA from
circulating and emerging IAVs by the human antibody 3I14. Somatic hypermutations play a
critical role in shaping the HCDR3, which alone and uniquely among VH3-30 derived anti-
bodies, forms contacts with five sub-pockets within the HA-stem hydrophobic groove. 3I14
light-chain interactions are also key for binding HA and contribute a large buried surface area
spanning two HA protomers. Comparison of 3I14 to bnAbs from several defined classes
provide insights to the bias selection of VH3-30 antibodies and reveals that 3I14 represents a
novel structural solution within the VH3-30 repertoire. The structures reported here improve
our understanding of cross-group heterosubtypic binding activity, providing the basis for
advancing immunogen designs aimed at eliciting a broadly protective response to IAV.
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Influenza A virus (IAV) is a persistent global health concerndue to its ability to rapidly mutate and year-round efforts arerequired to prepare for and combat seasonal strains. Despite
such effort, seasonal influenza viruses cause significant global
morbidity and mortality, as well as vast social and economic
burdens. In addition, the threat of a pandemic strain arising is an
endless concern because of large influenza reservoirs in swine and
avian populations1. Several avian IAVs have caused sporadic
human infections in the recent past, including H7N92, H5N13,
and H9N24. The H5N1 virus infected over 800 people between 2003
and 2019 with a human fatality rate of ~53% (https://www.who.int/
influenza/human_animal_interface/HAI_Risk_Assessment/en/),
whereas the H7N9 virus, which was first reported in China in 2013,
has over 1500 confirmed cases and ~39% human fatality rate (https://
www.who.int/csr/don/05-september-2018-ah7n9-china/en/).
More recently, strains of H6N1 (A/Taiwan/2/2013) and H10N8
(A/Jiangxi-Donghu/346/2013) have caused human infections5–8,
and although no fatalities from the H6 infections were reported,
the virus does have a slight preference for human receptors and
therefore may represent an intermediate towards a complete
human adaptation. Conversely, H10N8 has high genetic simi-
larity with the deadly H7N9 viruses and two of the three reported
H10N8 infections were fatal. Antiviral drugs can be used to treat
early stages of infection in an effort to mitigate epidemics and
pandemics; however, resistance has developed in most circulating
viruses to the M2 ion channel blocker adamantane9,10 and many
viruses also have resistance to neuraminidase inhibitors10,11.
Thus, there is an urgent need to advance efforts towards a more
universal solution for protection against IAV infections.
The envelope glycoprotein hemagglutinin (HA) is the major
target of the humoral immune response and is responsible for
receptor attachment and entry of IAVs12. HA is synthesized in an
inactive form (HA0) and then processed by intracellular proteases
to an active state, which consists of an apical globular head
domain (HA1) responsible for mediating receptor binding and a
stem domain (HA2) that harbors the fusion machinery. HA1 and
HA2 are linked by a single disulfide bond and assemble as trimers
of heterodimers. The head domain is immunodominant13, but
sequence diversity between IAVs and tolerance for antigenic
changes make the antibodies elicited towards the head typically
only viable towards highly related strains, although several
receptor-binding site targeting antibodies capable of neutralizing
diverse IAVs have been characterized14,15. The sequence diversity
in IAV is exemplified by the presence of 18 HA serotypes, which
can be further divided by phylogenetic relatedness into group 1
(including H1, H2, H5, H6, and H9) or group 2 (including H3,
H7, and H10).
Stem-directed broadly neutralizing antibodies (bnAbs), which
are elicited by natural infection and vaccination, tend to have a
wider breadth than head-directed antibodies and are often cap-
able of protecting against entire subtypes, groups, or even
types16–19. Stem-directed bnAbs prevent the release of viral
contents into the host cell by locking HA in a prefusion state, thus
inhibiting the structural rearrangement necessary to fuse to the
host endosomal membrane20. The VH1-69 class of stem-directed
bnAbs occurs frequently and many have been identified and
structurally characterized21,22. With the exception of CR911418
and 27F323, which target both group 1 and group 2 IAVs, the
majority of VH1-69 antibodies are specific for group 1. Germlines
VH6-1, VH1-18, and VH3-3024–26 have also shown bias use for the
production of stem-directed bnAbs and, unlike those derived
from VH1-69, both heavy and light chains are used for binding
HA, with some of these characterized antibodies capable of
neutralizing both group 1 and group 2 IAVs.
We recently reported on the discovery and in vivo efficacy of
the VH3-30-derived bnAb 3I1427. MAb 3I14 was isolated from H3
(A/Brisbane/10/2007) reactive memory B cells, neutralizes group
1 and group 2 IAVs in cell culture models, and protects mice
from viral challenge with lethal strains of H7N7-NL219, H7N9-
AH13, H3N2-BR07-ma, and H5N1-VN04 viruses27. Similar to
other stem-directed bnAbs, 3I14 prevents proteolytic cleavage of
HA0, inhibits a pH-induced conformational change in HA and
promotes antibody-dependent cellular cytotoxicity. A point
mutation in the light variable domain, termed 3I14D93N
(3I14D94N with prior numbering), was found to increase binding
affinity and viral neutralization potential by approximately ten-
fold against H5, with no negative effect on binding or
neutralization to H3.
In this work, we elucidate the structural determents for cross-
group binding of HA by 3I14 through solving the crystal struc-
tures of the 3I14 fragment antigen-binding region (Fab) com-
plexed with HA from group 1 (H6) and group 2 (H3 and H10).
We find that 3I14 uses a unique binding mechanism for recog-
nition of the HA stem, whereby only HCDR3 residues make
contacts within the hydrophobic groove, whereas the light chain
provides a large footprint spanning two HA protomers. 3I14 is
highly mutated and the location of these mutations in the heavy
and light chains mold the HCDR3 into the shape needed for
recognizing the HA stem. Structures of 3I14D93N bound to HA
from group 1 and group 2 reveal the molecular basis for enhanced
binding affinity towards H6. In addition, comparison of 3I14 with
other VH3-30-derived bnAbs, as well as bnAbs from diverse
germlines, reveals that 3I14 represents a unique example of a
stem-directed bnAb. This work broadens our understanding of
HA stem recognition by bnAbs and the structural diversity of
bnAbs that can be generated by the VH3-30 scaffold.
Results
Binding of 3I14 to human infecting H6 and H10 HAs. The
recent emergence into humans of avian H10N87 (A/Jiangxi-
Donghu/346/2013) (group 2) and H6N18 (A/Taiwan/2/2013)
(group 1) infections led us to investigate whether mAbs 3I14 and
3I14D93N could bind HA from each virus with similar binding
affinities as we observed with other HA strains27. Neither of these
HAs were included in our original characterization of 3I14,
although phylogenetically similar viruses to H6 (such as H1 and
H5) and H10 (such as H7, and H9) were studied27. This strain of
H6 has residue Glu39HA2, which in H5 led to the engineering of
3I14D93N and enhanced binding affinity; therefore, we hypothe-
sized that 3I14D93N may also bind H6 with improved affinity.
3I14 and 3I14D93N bound H10 with a similar equilibrium binding
constant (KD) of ~0.4 nM (Table 1 and Supplementary Fig. 1). In
contrast and as predicted, the wild-type 3I14 lost approximately
sixfold in the KD to H6, whereas 3I14D93N maintained this potent
binding affinity to H6 (~3 nM for wild-type 3I14 and 0.4 nM for
3I14D93N) (Table 1 and Supplementary Fig. 1).
To determine whether the improved binding affinity of the
3I14D93N mutant was a result of stabilization of the 3I14 IgG, we
measured the melting temperatures (TM) for wild-type 3I14 and
3I14D93N IgG. We found that the TM was 78 °C in each case
(Supplementary Fig. 2), signifying that the light-chain Asp93Asn
mutation does not impact the IgG thermostability. Rather, a
reduction in the antibody off-rate by approximately fivefold, with
little change in the on-rate, suggests a direct role for this residue
in binding HA.
Structure of 3I14 Fab in complex with group 1 and 2 HAs. To
investigate the structural basis for heterosubtypic recognition of
IAV by 3I14, as well as confirm the molecular details for the
enhanced binding affinity of 3I14D93N to H6, crystal structures
for the 3I14 and 3I14D93N Fabs in complex with HAs from group
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1, H6 (A/Taiwan/2/13), and group 2, H3 (A/Victoria/361/2011)
and H10 (A/Jiangxi/IPB13/2013) were solved. A total of four
complex structures permitted a thorough understanding of the
3I14- and 3I14D93N-binding modes: H3:3I14, H3:3I14D93N,
H6:3I14D93N, and H10:3I14 at resolutions of 3.5 Å, 3.2 Å, 3.5 Å,
and 4.2 Å, respectively (Table 2). The structures of the HA pro-
teins in each complex are similar to those of the apo structures,
which have been previously reported (Supplementary Fig. 3)28,29.
The electron densities for the H3 and H6 complexes are clear and
well-ordered at the HA:Fab interfaces, allowing for the com-
plementarity determining regions (CDRs) of 3I14 to be manually
built into the H3 bound structure (Supplementary Fig. 4). The
H10 structure has clear density for the C-α-backbone for both the
HA and Fab portions; however, side-chain residues are not well
resolved and some density is missing near the fusion peptide.
Therefore, our description of the intermolecular contacts is based
only on the H3 and H6 structures.
3I14 recognizes the stem of group 1 and 2 HAs in a manner
consistent with findings that it prevents proteolytic cleavage of
the HA precursor27 and in an overlapping region as other
reported stem-directed bnAbs22,24–26,30–32 (Fig. 1a and Supple-
mentary Fig. 5). The 3I14 epitope spans to a second HA
protomer, which results in a total buried interface area on HA of
980 Å2, consistent with the high binding affinity (Fig. 1b, c).
Heavy-chain interactions occur solely through contacts with
HCDR3, which buries a surface area of 481 Å2 in the hydrophobic
groove, between the middle and lower portions of Helix A, the
fusion peptide, and HA1.
The HCDR3 is 23 residues in length, with 5 residues (Tyr99,
Tyr100, Trp100G, Val100H, and Ala100J) (Kabat numbering)
making extensive van der Waals (vdW) and hydrogen-bonding
interactions (Fig. 2a, b). The reliance on HCDR3 for recognizing
the hydrophobic groove is in contrast to other stem-directed
bnAbs, which use a combination of heavy-chain or heavy- and
light-chain CDRs for interacting with similar portions on
HA18,22–24. The HCDR3 forms a six-residue loop extending
away from the hydrophobic groove consisting of residues
Phe100A through Val100F. At the center of the loop, Arg100D
protrudes along the fusion peptide and can make polar
interactions with the main-chain oxygen for either Val18 (group
2) or Ile18 (group 1). A contributing factor to the wide
neutralization breadth of 3I14 is the ability to accommodate
amino acid differences between group 1 and 2 HAs (Fig. 2a–d).
For example, Tyr100HCDR3 makes vdWs interactions with
Leu38HA2 (group 2) or the aliphatic side chain of Arg38HA2
(group 1) and Trp100GHCDR3 forms vdW contacts with Trp21HA2
and Ile45HA2 on helix A, as well as a hydrogen bond between the
main-chain oxygen with either Asn49HA2 (group 2) or Thr49HA2
(group 1). Val100H makes vdW contacts with Ile48HA2 and
Trp21HA2, whereas Ala100J makes vdW contacts with Leu52HA2
(group 2) or Val52HA2 (group 1). The main-chain oxygens for
Ala100JHCDR3 and Ser97HCDR3 each make hydrogen bonds with
the conserved residues Asn53 and Gln42, respectively. Another
contributing factor to effectively neutralizing group 1 and group 2
viruses is the local flexibility of HCDR3 at Trp100G, which
maintains an ~3–4 Å distance from the group-specific orientation
of Trp21HA (Supplementary Fig. 6). Collectively, the HCDR3
accounts for six hydrogen-bonding interactions and similar vdW
contacts in each complex.
The 3I14 light chain plays a prominent role in binding and
buries over half of the total surface area on HA (499 Å2), making
contacts through LCDR2, LCDR3, and LFR3. In particular, LFR3
is responsible for nearly half the light chain buried surface area by
mediating contacts with the adjacent protomer (Fig. 2c, d). This
large buried surface area of the light chain is uncommon, as
typically the heavy chain contributes more to binding than the
light-chain33. The 3I14 light chain is also able to accommodate
amino acid substitutions between group 1 and 2 HAs, such as
Arg54LCDR2, which forms a cross-protomer hydrogen bond with
the side chain of either Asp32HA1 (group 2) or Lys32HA1 (group
1). In addition, Ser63LFR3 hydrogen bonds with the side chain of
Gln33HA1 (group 2) or Asn33HA1 (group 1) on protomer 2 and
Ser67LFR3 hydrogen bonds with the side chain of Glu35HA1
(group 2), whereas Ser65LFR3 can hydrogen bond with Gln25HA1
(group 1). Despite the long span of the 3I14 epitope, the serine
residues along LFR3 are able to accommodate the group 1 glycan
located on Asn33HA1 of the second HA protomer, whereas more
bulky residues on LFR3 would likely result in a steric clash,
preventing such extensive cross-protomer interactions, and
possibly limiting the ability of 3I14 to bind.
Role of somatic mutations in shaping HCDR3. 3I14 is encoded
by the IGHV3-30*18 and IGLV1-44*01 germline genes. The
HCDR3 uses the IGHD3-22*01 DH segment flanked by large N-
additions at both VH and IGHJ4*02 junctions27. We previously
reported that germline reversions of somatic hypermutations
(SHMs) for either the heavy chain (13 SHMs) or light chain (7
SHMs) resulted in a 2- to 7-fold reduction in binding affinity to
H3 and H5, whereas simultaneous reversion of both chains to
germline decreased binding affinities by approximately 14-fold in
either case27. Six of the seven light-chain SHMs are in LCDR2
and LFR2, and mapping them on the structure showed that they
cluster at the interface with the heavy chain (Fig. 3a, b). The
exception is Gly30LCDR1, which is mutated from a serine in the
germline and appears to prevent either a steric clash or the polar
serine side chain from pointing towards the aliphatic side chain of
Lys39HA2 (group 2) or Glu39HA2 (group 1) (Supplementary
Fig. 7). Due to the location for majority of these SHMs, one
possible consequence is the stabilization of the 3I14 heavy–light
chain interface, which has been shown to be a critical feature in
antibody affinity maturation34,35.
Heavy-chain SHMs are spread across HCDR1, HCDR2, FR3,
and HCDR3 (Fig. 3a, b). Although HCDR1 and HCDR2 do not
directly interact with HA, the SHMs occur at positions that
seemingly “mold” the HCDR3 into the conformation needed to
recognize the large area within the hydrophobic groove (Fig. 3c).
When viewed along with the light-chain SHMs, the HCDR3 is
sandwiched between seven total mutations, including a pocket
formed by the light-chain somatically mutated residues His34LFR2
and Phe36LFR2, which may serve to anchor Pro96HCDR3. The large
decrease in binding affinity obtained with either heavy- or light-
Table 1 Binding data for 3I14 and 3I14D93N.
3I14 Variant H6 (A/Taiwan/2/2013) H10 (A/Jiangxi-Donghu/346/2013) H3 (A/Perth/16/2009)a
Ka (M−1 s−1) Kd (s−1) KD (nM) Ka (M−1 s−1) Kd (s−1) KD (nM) Ka (M−1 s−1) Kd (s−1) KD (nM)
3I14 WT 5.19 × 104 1.52 × 10−4 2.9 1.13 × 105 5.38 × 10−6 0.48 1.52 × 105 3.99 × 10−5 0.26
3I14D93N 6.90 × 104 3.08 × 10−5 0.45 1.23 × 105 5.00 × 10−6 0.41 1.77 × 105 5.44 × 10−5 0.31
aReported by Fu et al.27.
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Table 2 X-ray data collection and crystallographic refinement statistics.
H3_3I14 H3_D93N H6_D93N H10_3I14
PDB ID 6WF0 6WEZ 6WEX 6WF1
Data collection
Space group P63 P63 R32 P321
Cell dimensions
a (Å) 130.32 130.84 117.81 127.02
b (Å) 130.32 130.84 117.81 127.02
c (Å) 188.55 189.34 438.26 158.37
α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (Å) 42.66–3.46 (3.58–3.45) 39.02–3.21 (3.32–3.21) 48.26–3.49 (3.60–3.49) 41.58–4.19 (4.34–4.19)
Unique reflections 23,612 (2349) 29,818 (2918) 15,294 (1421) 9561 (775)
Total reflections 130,821 (12,953) 140,225 (14,027) 144,741 (13,615) 32,231 (1783)
Rmerge 0.196 (0.992) 0.141 (1.147) 0.168 (0.649) 0.110 (0.581)
Rpim 0.090 (0.459) 0.072 (0.581) 0.058 (0.219) 0.063 (0.406)
I/σI 8.9 (1.7) 10.2 (1.2) 9.9 (3.2) 8.8 (1.5)
CC1/2 0.989 (0.390) 0.996 (0.596) 0.995 (0.86) 0.987 (0.646)
Completeness (%) 99.1 (98.7) 98.8 (97.6) 99.3 (94.5) 84.5 (70.2)
Redundancy 5.5 (5.5) 4.7 (4.8) 9.5 (9.6) 3.4 (2.3)
Refinement
Resolution (Å) 42.66–3.46 39.02–3.21 48.26–3.49 41.58–4.19
Unique reflections 23,516 (2353) 29,741 (2964) 15,291 (1421) 9564 (778)
Rwork/Rfree 0.231/0.282 0.232/0.281 0.276/0.333 0.261/0.309
No. atoms:
Protein 6959 6959 7109 6959
Ligand 211 206 14 14
B-factors (Å2)
Average 100 95 112 244
Hemagglutinin 79 73 86 235
Glycans 121 111 108 257
Antibody 124 120 145 256
R.m.s. deviations
Bond lengths (Å) 0.003 0.003 0.002 0.002
Bond angles (°) 0.66 0.68 0.63 0.49
Ramachandran
Favored (%) 92.16 94.92 92.31 94.51
Allowed (%) 7.84 5.08 7.58 5.49
Outliers (%) 0 0 0.11 0
R.m.s. deviations root-mean-square deviations.
*Values in parentheses are for highest-resolution shell.
Fig. 1 3I14 recognition of group 1 and group 2 HA proteins. a X-ray structure of H3 hemagglutinin bound by Fab 3I14. One HA protomer is shown in
cartoon with HA1 colored orange and HA2 colored red. The other two HA protomers are shown in surface representation and colored white or gray. 3I14 is
shown in surface representation with heavy chain colored blue and light chain colored green. b Zoomed in view of the box from a showing the H3-3I14
interface and the major structural elements of HA, which are recognized. Helix A is colored red, the fusion peptide is colored cyan, HA1 is colored orange,
and a second HA protomer is colored gray. The 3I14 CDRs are shown as cartoons. A group 2-specific sugar residue at position 38 of HA1 is labeled as
NAG38*. c Similar view as in b showing the H6-3I14D93N interface. A group 1-specific sugar on the second HA protomer, which interacts with 3I14 is
labeled as NAG33*.
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chain germline-reverted mutants could therefore be due to
plasticity of the HCDR3 that may result from the lack of some, or
all, of these interactions.
Molecular basis for improved binding affinity of 3I14D93N to
H6. The 3I14D93N mutant shows increased binding affinity
towards recombinant H6, while retaining similar binding affinity
towards H3 and H10, which was anticipated based on our pre-
vious studies27. In the H6-bound structure, the electron density
around Asn93LCDR3 is well resolved and shows a hydrogen bond
being formed with Arg38HA2 (Fig. 4a). The paratope–epitope
surface potentials are each relatively neutral, with the local
environment of 3I14D93N being slightly negative despite the
positively charged Asn93 substitution (Fig. 4a). In addition, the
residues on HA in close proximity to Arg38HA2, namely Glu39
and Asp37, diminish the positive charge that Arg38 would carry,
thus facilitating better charge complementarity with 3I14D93N
and explaining the improved binding characteristics.
In the H3-3I14D93N structure, the Asn93LCDR3 forms a
hydrogen bond with Lys39HA, and consistent with the H6-
3I14D93N structure, reveals a negatively charged contact surface
for LCDR3, whereas in this case the H3 surface is positively
charged (Fig. 4b). In the H3-3I14 wild-type structure, Asp93LCDR3
does not hydrogen bond with Lys39HA, evident by the clear
electron density around each side chain (Fig. 4c). Rather, Lys39HA
assumes an alternate rotamer with the side chain extending
towards the 3I14 LCDR1 and forming a hydrogen bond with
Asn32LCDR1. This orientation extends the Lys39HA side chain
towards the center of the negative patch formed by Asp93LCDR3
and Asn31LCDR1. The ability for Lys39HA to adopt multiple
Fig. 2 Binding comparison of 3I14 and 3I14D93N with group 2 and group 1 HAs. a, b 3I14 HCDR3 interactions with either group 2 H3 (a) or group 1 H6 (b)
HAs. The 3I14 HCDR3 is colored blue with residues that make either polar or vdWs interactions shown as sticks and labeled in blue. The HA helix A is
shown in cartoon and colored red, the fusion peptide is colored cyan, HA1 is colored orange, and the group 2-specific glycan is shown as yellow spheres.
Helix A residues that make polar interactions are shown as yellow sticks, whereas vdWs contacts are shown as red sticks. Dashed lines indicate hydrogen
bonds. Residues that differ between group 1 and group 2 HAs are indicated with an asterisk. c, d 3I14 LCDR2 and FR3 interactions, highlighting cross-
protomer contacts. 3I14 light chain is colored green and shown as cartoon with green labels. HA coloring and labels follow that of (a, b), except the group 1-
specific glycan is shown as yellow sticks. Protomer 2, which is buried by FR3, is colored gray.
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rotamers and for 3I14 and 3I14D93N to retain a hydrogen bond
interaction in either instance explains the similar binding
affinities for each antibody towards group 2 HAs.
Comparison of 3I14 binding with other VH3-30 derived bnAbs.
3I14 is the fourth bnAb to be structurally characterized which
utilizes the VH3-30 germline gene, along with mAbs 3.1, 39.39,
and FI6v3 (stabilized version of FI6)24–26. MAb 3.1, which was
selected by phage display shows heterosubtypic neutralization
against the H1a clade (H1, H2, H5, H6) and some H9 subtypes,
whereas 39.39 and FI6v3 each neutralize group 1 and 2 viruses.
To better understand how the developmental pathways for each
of these VH3-30 bnAbs leads to broad HA recognition, the
HCDR3 length, the percentage of residues in the heavy and light
chains that undergo SHM, and the paratope buried surface areas
were compared. This analysis revealed few distinguishing features
other than 3I14, FI6v3, and 39.29 each contributing ~200–600 Å2
of paratope light-chain buried surface area (Supplementary
Fig. 8). However, the angle of approach for each antibody towards
the HA stem differs. With respect to 3I14, the VH domains for
39.29, FI6v3, and 3.1 are rotated by ~42o, 49o, and 62o, respec-
tively, with FI6v3 and 3.1 each rotating counterclockwise, and
39.29 rotating clockwise (Fig. 5a–d, top). In addition, FI6v3
approaches HA in a perpendicular manner, whereas each of the
other antibodies is angled ~20–45o towards the HA head domain.
The angles of approach result in distinct but overlapping foot-
prints on the HA stem, covering regions of HA1 and HA2. MAb
39.29 buries ~1100 Å2 on HA, whereas FI6v3 buries ~820 Å2 and
3.1 buries ~920 Å2 (Fig. 5a–d, bottom). The angle taken by mAb
3.1 results in the HA buried surface being nearly evenly split
between HA1 and HA2; however, a potential clash with the
conserved group 2 glycan at Asn32 likely contributes to group
1 selectivity. FI6v3 makes contacts with an adjacent protomer,
albeit to a lesser extent than seen with 3I14 (230 Å2 for 3I14 vs.
90 Å2 for FI6).
Although approaching from different angles, each antibody
does make extensive contacts within the HA hydrophobic groove.
These interactions can be summarized by contacts with five sub-
pockets, numbered as one through five starting from the top of
helix A, distal from the membrane proximal region (Fig. 6a–d).
Of note, each antibody shares the same VH–JH gene segment
usage (VH3-30, JH4)24–26 and variable DH segments, which results
in HCDR3s that are utilized for binding pockets two and three,
centering around contact with Trp21HA (Fig. 6e). Interactions
with the remaining pockets are not conserved and take a variety
of forms. For instance, 3I14 exclusively utilizes HCDR3 to
interact with each of the five pockets, whereas FI6v3 and 39.39
incorporate light-chain CDRs and 3.1 engages HCDR1.
Another distinguishing feature for 3I14 is that the HCDR3 is
flipped ~180o compared to the other VH3-30 antibodies, a
reflection of the different approach angles (Fig. 6a). Although
FI6v3 most closely resembles 3I14 by predominately utilizing
HCDR3 (residues Arg99, Leu100A, Phe100D, and Trp100F) for
pockets one through four, interaction with pocket five requires
recruitment of the somatically mutated residue Arg93LCDR1
(Fig. 6b). An Arg93Ser germline-reverted mutant was shown to
have a decrease in binding affinity to group 2 HAs by a factor of
44, thus demonstrating the importance for this specific interac-
tion in the maturation of FI625.
Comparison with stem-directed antibodies from other germ-
lines. Next, the hydrophobic groove interactions between the
3I14 VH    QVQLLESGGG VVQPGRSLRL SCAASGFTFS NYGMHWVRQA PGKGLEWVAI ISFDGSKKYY ANSVKGRSTI
3I14 VHGL  ....V..... .......... .......... S......... .........V ..Y...N... .D.....F..
3I14 VH SRDNSKNTLS LQMNSLGPED TALYYCAKLP SPYYFDSRFV WVAASAFHFW GQGILVTVSS
3I14 VHGL  .........Y ......RA.. ..V....R.. ....Y..SGY YY...Y.DY. ...T......
3I14 VL    NFMLTQPPSA SGTPGQRVTI SCSGSSSNIG GNTVHWFQQL PGTAPKLLIY TNSLRPSGVP DRFSGSKSGT
3I14 VLGL  QSV....... .......... .......... S...N.Y... .......... S.NQ...... ..........
3I14 VL SASLAISGLQ SEDEADYYCA AWDDSLNGQV FGGGTKLTVL
3I14 VLGL  .......... .......... ........W. .......... 
Fig. 3 3I14 Somatic hypermutations shape HCDR3. a Sequences for 3I14 heavy- and light-chain wild type and germline. Somatic hypermutations (SHMs)
are in bold. b SHMs on the 3I14 heavy and light chains are shown as white sticks and labeled. c Zoomed in box from b showing the SHMs that surround the
HCDR3 as white transparent surfaces and sticks. HCDR3 is shown as a cartoon and sticks. The HCDR3 is shaped by interactions with the SHMs, which
surround it.
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VH3-30-derived antibodies with antibodies from germlines
that fall into specific antibody classes were compared (Fig. 7a–d).
VH1-69-derived antibodies, such as CR911418 and 27F323, con-
tain an IFY motif consisting of an HCDR3 tyrosine (Y) located at
position 98 or 99 coupled with HCDR2 residues Ile54 (I) and
Phe55 (F) (Fig. 7b). As with all the stem-directed antibodies,
which have been characterized from this class, CR9114 and 27F3
utilize HFR3 and HCDR2 for majority of the contacts within the
hydrophobic groove and do not share extensive molecular simi-
larities with any of the VH3-30 antibodies. The only similarity
with 3I14 is the HCDR3 tyrosine used for binding pocket four.
The VH6-1- and VH1-18-derived antibodies, on the other hand,
utilize molecular signatures, which are shared by 39.29 and FI6v3,
respectively. Medi8852 and 56.a.09 are representative of the VH6-
1+HD3-3 class of antibodies that use the same FGV/I motif as
39.29, where an HD3-3 encoded phenylalanine recognizes pocket
2, and either a germline-encoded valine or the SHM-altered
isoleucine binds pocket 3 (Fig. 7c). The VH1-18 germline contains
multiple classes, including the HD3-9 class such as antibody S9-3-
37, which harbors an LXYFXWL motif22 (Fig. 7d). FI6 falls into
this class, which results in placement of Tyr and Phe into pockets





































Light Chain H3 HA2 
Light Chain H3 HA2 
N32 
LCDR1 
Fig. 4 3I14 and 3I14D93N binding to H6 and H3 HAs. a H6-3I14D93N complex; b H3-3I14D93N complex; c H3-3I14 wild-type complex. Left panels show the
LCDR3 as green cartoon and sticks, and HA shown as red cartoon and sticks. 1σ 2Fo–Fc electron densities are shown in blue. Hydrogen bonds are depicted
as yellow dashed lines. Panel on the right is an electrostatic surface representation of the image from the left.
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harboring this motif, does share the Tyr and Phe interactions.
Antibody 31.b.09 (Fig. 7d) also utilizes the HD3-9 gene
(translated in a different reading frame than S9-3-37 and FI6)
and harbors an ILTG motif, which places Leu in pocket three
rather than a Phe. Mab 16.g.07 (VH1-18, D2-15, JH2) is of a multi-
donor class that shares a SHM-derived Thr52HCDR2 and an
HCDR3 QXXV motif22 (Fig. 7d). The binding for 16.g.07 appears
most similar to mAb 31.a.83 (VH3-23, D3-9, JH6) (Fig. 7e), which
is currently characterized as a unique lineage22 and binds the
hydrophobic groove primarily through HCDR3 (Fig. 7e).
In summary, this comprehensive comparison reveals that the V
(D)J arrangement for the VH3-30 antibodies can develop multiple
signatures to target the HA stem. In some cases, these
HCDR3 signatures converge on similar structural solutions that
have been utilized by other VH germline segments. 3I14 is
exclusive in the ability to solve this landscape problem by reverse
orientation of the HCDR3 and in doing so makes contact with all
five hydrophobic pockets. In addition, the 3I14 light chain
promotes cross-protomer binding and proper positioning of the
HCDR3 into the stem groove. At present, 3I14 falls into an
uncharacterized class that represents a unique example among
the VH3-30-derived bnAbs.
Discussion
Broadly neutralizing human mAbs targeting the stem region of
influenza HA provide opportunities for antibody-based ther-
apeutics against yearly circulating IAV strains and treatment for
novel emerging HA subtypes from zoonotic sources. Structural
information obtained from antibody-HA complexes may also
guide the rational design of a sought-after universal vaccine,
which could protect across strains within an influenza subtype,
across subtypes within IAV groups, or across all influenza A and
B viruses.
In this study, we elucidated the structural basis for hetero-
subtypic recognition of HA by the VH3-30-derived mAb 3I14,
which was originally isolated from human memory B cells27.
Structures of 3I14 in complex with group 1 H6 as well as group 2
H3 and H10 yielded the expected result in that 3I14 recognizes
HAs from each strain in a highly similar manner, consistent with
other antibodies targeting stem and non-stem epitopes that have
been reported elsewhere22,25,30,36,37. The 3I14 heavy-chain
interactions consist solely of HCDR3 contacts within five sub-
pockets of the stem hydrophobic groove, whereas the light chain
makes contacts on helix A and extensive cross-linking interac-
tions on an adjacent HA protomer. Antibody CT149 has also
been shown to bury ~250 Å2 of the same adjacent protomer32;
however, compared with 3I14, CT149 has vast differences in
overall HA recognition. CT149 approaches HA at a different
angle, which permits light-chain contacts with HA1, whereas the
heavy chain makes fewer contacts within the stem hydrophobic
groove (Supplementary Fig. 9).
An engineered LCDR3 point mutant, 3I14D93N, shows a
sevenfold increase in binding affinity towards H6, while retaining
binding to H10 and H3. A single hydrogen bond and better
charge complementarity between 3I14 and H6 are the driving
force for the improvement. Importantly, this mutation could be
generated in somatic B cells in vivo by activation-induced dea-
mination (AID) U:G mismatch repair38. Similar improved
binding affinity for 3I14D93N to H5 (which is highly conserved
with H6 at the 3I14 binding interface) also resulted in tenfold
higher potency in a pseudotyped virus neutralization assay27.
This correlation between binding and neutralization makes
3I14D93N a more attractive option for development as a ther-
apeutic or prophylactic for treatment of severe IAV infection, as
passive immunization with anti-HA antibodies has shown pro-
mising effects39. In addition, the 3I14 HCDR3 might be con-
sidered as a next-generation scaffold to produce small molecules
Fig. 5 Angles of approach towards HA for VH3-30 BnAbs. a–d Top: angles of approach for each of the VH3-30 antibodies (H3-39.29, PDB 4KVN; H3-
FI6v3, PDB 3ZTJ; H1-3.1, PDB 4PY8). HA is shown in surface representation with HA1 and HA2 from the primary protomer colored orange and red,
respectively. Each Fab is shown in cartoon representation with 3I14 colored as in Fig. 4, and 39.29, FI6v3, and 3.1 colored according to the labels. The
degrees shown in figures b–d is the rotation necessary to superimpose the VH domain of that antibody onto the VH domain of 3I14, as determined in Coot.
Bottom: HA portion for each complex from the top panel, rotated ~45o. The buried surface area for each antibody is colored cyan on HA. The black arrows
in a and c indicate cross-protomer interactions.
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with cross-group therapeutic potential, such as the cyclic peptidic
fusion inhibitors recently reported40.
Recognition of the HA stem hydrophobic groove by 3I14 is
similar to group-specific and more broadly reactive antibodies
from diverse germlines18,22,23,30, as well as that from the three
other VH3-30-derived antibodies that have structures reported
(FI6v3, 39.29, and 3.124–26). VH3-30 bnAbs do not interact with
HA using HCDR2, whereas the use of HCDR2 can infer that a
germline is inherently fit for pathogen interaction, such as the
“IF” portion of the IFY motif in VH1-69-derived bnAbs21,41.
Comparison of 3I14 with FI6v3, 39.29, and 3.1 complexes
shows that they each have different HCDR3s and CDR-binding
contributions to the hydrophobic groove, different light chains
that contribute differently to binding, varying angles of
approach, and distinct but overlapping footprints on HA.
Despite different developmental pathways, a key similarity for
the VH3-30-derived bnAbs is a shared VH–JH gene segment
usage, which can combine with variable DH segments to pro-
duce HCDR3 peptides, which preferentially recognize pockets
near Trp21. Notably, FI6v3 and 39.29 each contain HCDR3s
with defined molecular signatures, grouping them with the
FGV/I motif (VH1-18), and the LXYFXWL motif (VH6-1),
respectively. The ability for VH3-30-derived bnAbs to develop a
range of signatures that are shared with divergent germlines
provides additional insights towards the plasticity of this V-
segment scaffold.
Fig. 6 Structural comparison of VH3-30-derived bnAbs bound to HA. a H3-3I14; b H3-FI6v3; c H3-39.29; d H1-3.1. All VH3-30-derived antibodies
recognize the hydrophobic groove between helix A and the fusion peptide. CDRs are shown as cartoons with residues interacting with sub-pockets
(labeled as 1 through 5) shown as sticks. The fusion peptide is colored cyan with Trp21 shown as sticks; helix A is colored red and HA1 is colored orange.
e Sequences for antibody CDRs, which have at least one residue that interacts with a sub-pocket. Highlighted residues coincide with which HA subpocket
the interaction occurs: pocket 1-red; pocket 2-cyan; pocket 3-green; pocket 4-yellow; and pocket 5-purple.
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Similar to many stem-directed antibodies, 3I14 provides pro-
tection from influenza through Fab- and Fc-mediated interac-
tions27. In a mouse model, Fc-mediated effector functions are
required for protection from influenza by both stem- and head-
directed antibodies42. However, not all antibodies providing a
protective effect are found to neutralize the virus in vitro18,42,
suggesting that screening based on heterotypic binding and
in vitro neutralization may fail to identify antibodies providing
the greatest protective effect. Shifting the focus from bnAbs to
broadly protective antibodies will be important when evaluating
the effectiveness of a vaccination strategy or to identify antibodies
with therapeutic potential.
Antibodies targeting conserved epitopes on the HA stem are an
important part of the immune response to influenza infection and
vaccination43,44. However, in either case, the immune system has
a preference for non-stalk epitopes, thus posing an immunolo-
gical obstacle towards universal vaccine efforts45,46. This might be
overcome through thoughtful antigen design and heterologous
prime boost vaccination strategies, such as the headless and

























































































































IFY IFY FGV/I FGV/I 
FGV/I 
Q102 
Fig. 7 Comparison of the 3I14 HA stem hydrophobic groove interactions with other stem-bound antibodies. a VH3-30 interactions with the hydrophobic
groove are shown with heavy and light-chain CDRs colored as in Fig. 6. The HA stem is shown in surface representation and colored by electrostatic charge
(red-negative, blue-positive, white-neutral). Residues interacting with pockets 1–5 are circled with a dotted line and labeled. b Antibodies CR9114 (PDB
4FQI) and 27F3 (PDB 5WKO) from the VH1-69 germline are shown. c Antibodies Medi8852 (PDB 5JW4) and 56.a.09 (PDB 5K9K) from the VH6-1
germline. d VH1-18 antibodies 31.b.09 (PDB 5K9O), S9-3-37 (PDB 6E3H), and 16.g.07 (PDB 5KAN). e The VH3-3 antibody 31.a.83 (PDB 5KAQ). For b–e, the
heavy-chain CDRs are colored blue and the light-chain CDRs are colored green. The molecular signature is indicated below each figure or indicated as
unique if no signature has been identified.
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specific immune responses in preclinical settings47–53. Another
possibility might be germline-targeted immunogens, such as
those being developed for HIV54–56, to activate germline pre-
cursors, which could then be expanded upon with subsequent
vaccinations. The structural definition of the 3I14 epitope adds to
the growing knowledge base of antigenic determinants necessary
for eliciting antibodies, which have the ability to confer protection
against circulating and emerging strains of IAV and should
provide new insights to ongoing universal vaccine design efforts.
Methods
Fab expression and purification. 3I14 and 3I14D93N Fabs were individually cloned
into pFastBac Dual vectors (Invitrogen) with an N-terminal honeybee melittin
signal peptide fused to the light chain and a GP64 signal peptide fused to the heavy
chain, along with a C-terminal His6-tag also fused to the heavy chain. Recombinant
bacmid DNA was generated using the Bac-to-Bac system (Invitrogen) and bacu-
lovirus was generated by transfecting purified bacmid DNA into Sf9 cells using
Cellfectin II (Invitrogen). Fabs were expressed by infecting suspension cultures of
High Five cells (Invitrogen) with baculovirus shaking at 110 r.p.m. for 72 h at 28 °C.
The proteins were purified by Ni-NTA (Qiagen), followed by gel filtration (GE
Healthcare) in 10mM HEPES pH 7.5, 150mM NaCl, and 5% glycerol.
Expression and purification of HAs for crystallization. The HA0’s from H3 (A/
Victoria/361/2011), H6 (A/Taiwan/2/13), and H10 (A/Jiangxi-Donghu/346/2013)
were codon optimized and cloned into pFastBac vectors for expression in High Five
insect cells. All constructs were fused with an N-terminal gp64 signal peptide, a C-
terminal thrombin cleavage site, followed by a foldon trimerization sequence, and a
His6-tag, as also described previously57. HA0s were purified via His-tag affinity
chromatography, digested overnight with trypsin (New England Biolabs, 5 mU
trypsin per mg HA, 16 h at room temperature) to remove the His-tag/trimerization
domain and ensure a uniform population of HA1/HA2. HAs were then run over a
gel filtration column and found to be >95% pure by SDS-polycrylamide gel elec-
trophoresis (PAGE) analysis.
Crystallization and structural determination of HA-Fab complexes. For 3I14
Fab-HA or 3I14D93NFab-HA complex formation, Fab was added to HA in a molar
ratio of 3.5 : 1, to achieve three Fabs per HA trimer, incubated at room temperature
for 1 h or overnight at 4 °C, and the complex was then purified from unbound Fab
by gel filtration in buffer containing 10 mM HEPES pH 7.5, 150 mM NaCl, and 5%
glycerol. Protein complexes were concentrated to 10 mg/mL and sitting drop vapor
diffusion screens for all complexes were set up using a Phoenix liquid handler (Art
Robbins Instruments) at a protein to buffer ratio of 1 : 1 and stored at 20 °C.
H3-3I14 Fab crystals appeared within 3–5 days and were optimized via the
hanging drop method in buffer containing 18–24% w/v PEG 3350, 0.2 M KCN, and
0.1 M Bis-Tris-Propane pH 7.5. Crystals were cryoprotected in mother liquor
supplemented with 20% glycerol, flash-cooled in liquid nitrogen. X-ray diffraction
data were collected to 3.7 Å resolution at the 19BM-D beamline (wavelength
0.97919 Å) at the Advanced Photon Source (APS) and were processed in space
group P63 using XDS58. The structure was determined by molecular replacement
with Phaser59, using the following search models: (i) a homology model of the
variable region of 3I14 built using the PIGs server60, which had the HCDR3
removed; (ii) the Fab constant region from PDB 4PY8; and (iii) a single H3
protomer from PDB 4O58. One HA protomer (HA1/HA2) of the HA trimer was
found in the asymmetric unit, along with one 3I14 Fab. After initial rounds of rigid
body refinement with Phenix61, unbiased density from the Fo–Fc map was used to
build the 3I14 Fab HCDR3, as well as for building of N-linked glycans to H3. The
model was iteratively rebuilt for several more rounds using Coot62 and refined
using Phenix, with final Rwork/Rfree values of 0.231/0.282, respectively.
H3-3I14D93N Fab complex was found to crystalize in the same condition as
native 3I14 Fab-H3 described above. Crystals were cryoprotected in mother liquor
supplemented with 20% glycerol, flash-cooled in liquid nitrogen. X-ray diffraction
data were collected to 3.3 Å resolution at the 19BM-D beamline (wavelength
0.97919 Å) at APS and were processed in space group P63 using XDS58. The
structure was determined by molecular replacement with Phaser using the solved
H3-3I14 structure as a search model, with the mutant D93N residue of 3I14
omitted. The model was refined with Phenix, and residue N93 and glycans were
built using Coot. Iterative rounds of refinement resulted in Rwork/Rfree values of
0.232/0.281, respectively.
H6-3I14D93N Fab complex crystals appeared in 3–5 days from a drop
containing 0.1 M MIB Buffer (sodium malonate, imidazole, and boric acid in the
molar ratios 2 : 3 : 3) pH 5.0 and 25% PEG 1500. Crystals were cryoprotected in
mother liquor supplemented with 20% glycerol and flash-cooled in liquid nitrogen.
X-ray diffraction data were collected to 3.8 Å resolution at the 19BM-D beamline
(wavelength 0.97919 Å) at APS and were processed in space group R32 using XDS.
The structure was determined by molecular replacement with Phaser, using a single
protomer of H6 from PDB 4XKD, and the solved portion of 3I14D93NFab from the
complex with H3. One HA protomer (HA1/HA2) of the HA trimer was found in
the asymmetric unit, along with one 3I14D93NFab. Iterative rounds of reciprocal
space and real-space refinement were carried out using Phenix and Coot,
respectively, resulting in Rwork/Rfree values of 0.276/0.333, respectively.
H10-3I14 Fab complex crystals appeared in 3–5 days from a drop containing
15% w/v PEG 4000, 0.15M ammonium sulfate, 0.1 M MES pH 6. Crystals were
cryoprotected in mother liquor supplemented with 20% glycerol and flash-cooled
in liquid nitrogen. X-ray diffraction data were collected to 4.2 Å resolution at the
23ID-B beamline (wavelength 1.033202 Å) at APS and were processed in space
group P321 using HKL300063. The structure was solved by molecular replacement
in Phaser, using a single protomer of H10 from PDB 5TGV as one search model
and the solved 3I14 Fab structure from the above H3 complex as the other search
model. Real-space and reciprocal space refinement were carried out using Phenix
and Coot, with final Rwork/Rfree values of 0.261/0.309, respectively.
X-ray data collection and refinement statistics are listed in Table 1. Structural
illustrations were prepared using PyMol64. Antibody–antigen interface analysis was
carried out using the Protein Interfaces, Surfaces and Assemblies software, PISA,
obtained from the European Bioinformatics Institute65. Prism 7.0 was used for
graphical representation to compare buried surface area, CDR lengths and SHMs.
Expression and purification of 3I14 and 3I14D93N IgG antibodies. Gene frag-
ments for either 3I14 or 3I14D93N were separately subcloned into human IgG1
expression vector TCAE666. The IgG1s were expressed in 293F cells (ThermoFisher,
catalog number R79007) by transient transfection and purified by protein A sepharose
affinity chromatography followed by buffer exchange into phosphate-buffered saline
(PBS) using amicon ultra centrifugal filters with a 50 K molecular weight cut-off.
Biolayer interferometry. Kinetic analyses of 3I14 and 3I14D93N binding to
recombinant HAs were performed on biolayer interferometry using an
OctetRED96 instrument (ForteBio, Menlo Park, CA) at 25 °C. The 3I14 and
3I14D93N IgG were diluted to 5 nM in Pierce protein-free blocking buffer (PBS with
0.5% (v/v) Tween-20) and then captured onto anti-human IgG Fc (AHC) bio-
sensors (Fortebio) for 180 s. Binding of recombinant full-length HAs were probed
at seven concentrations that were serial diluted starting at 100 nM for H6
experiments and 50 nM for H10 experiments. All experiments contained an
additional anti-human IgG Fc antibody biosensor that tested for potential non-
specific interactions between HAs and anti-human IgG Fc. For the measurement of
the association rate constant (Kon), association of 3I14 was measured for 300 or
600 s, and for the measurement of Koff, dissociation of 3I14 IgG1 was measured for
700 or 1200 s. Data were reference-subtracted and aligned with each other in the
Octet Data Analysis software v11.0 (FortéBio) using a 1 : 1 binding model. All
binding traces and curves used for fitting are reported in Supplementary Fig. 1.
Extrinsic fluorescence assay. Experiments were carried out as described for high-
throughput thermal scanning67. Specifically, SYPRO Orange dye (Invitrogen) was
supplied in dimethylsulfoxide at 5000× the working concentration for PAGE
staining. Samples of 20 μL per well were prepared by mixing 1 μL of 200× SYPRO
Orange (final concentration 10×) with 19 μL of protein (0.1 mg/mL or 2.1 μM) in
PBS. Spectra were obtained on a Bio-Rad CFX96 thermal cycler Real-Time
Detection System. Thermal denaturation curves (ramp rate of 1 °C/min at 0.2 °C
intervals with an equilibration of 5 s at each temperature before measurement)
were acquired by measuring fluorescence intensities using the Förster resonance
energy transferchannel with excitation from 450 to 490 nm and detection from 560
to 580 nm. Melting temperatures are reported as the average, ±SD from four
independent measurements.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The atomic coordinates and corresponding structure factors have been deposited into the
Protein Data Bank with PDB accession codes 6WF1, 6WF0, 6WEX, and 6WEZ.
Structures used for molecular replacement can be found under PDB accession codes
4PY8, 4O58, 4XKD, and 5TGV. Structures used for comparison and analysis can be
found under PDB accession codes 4KVN, 3ZTJ, 4PY8, 4FQI, 5WKO, 5JW4, 5K9K,
5K9O, 6E3H, 5KAN, and 5KAQ. Other data are available from the corresponding
authors upon reasonable request. Source data are provided with this paper.
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